Whalen Matthew Pratt

Whalen Matthew Pratt is listed in filings as Director at Telomir Pharmaceuticals, Inc. Common Stock. This profile follows SEC Form 4 activity through May 22, 2026, including 3 public disclosures. Recent filings connect the profile to Telomir Pharmaceuticals, Inc. Common Stock (TELO) and MIRA Pharmaceuticals, Inc. (MIRA). The current snapshot covers public activity from Dec 10, 2024 to May 22, 2026. Reported amounts are shown as $125.5K to $29.8K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.